Loading
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Previous close
$1.36
+$0.01 · +0.74%
Regular session · ET · Market data may be delayed.
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Day range
Current $1.36
52-week range
Current $1.36
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
63
Undervalued
Sentiment
60
Mixed
Risk
71
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Day range
Current $1.36
52-week range
Current $1.36
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 10.02M EUR | 4.52M EUR | 4.35M EUR | 3.08M EUR | 852K EUR |
| Cost of goods sold | 3.69M EUR | 1.55M EUR | 1.66M EUR | 1.15M EUR | 303K EUR |
| Gross profit | 6.33M EUR | 2.97M EUR | 2.69M EUR | 1.93M EUR | 549K EUR |
| Research and development | 42.82M EUR | 34.33M EUR | 27.66M EUR | 15.86M EUR | 5.95M EUR |
| Selling, general, and administrative | 46.44M EUR | 28.46M EUR | 20.65M EUR | 18.86M EUR | 11.11M EUR |
| Operating expenses | 89.27M EUR | 61.78M EUR | 47.79M EUR | 34.43M EUR | 26.79M EUR |
| Interest income | 1.83M EUR | 2.5M EUR | 2.57M EUR | 372K EUR | 1K EUR |
| Interest expense | 1.69M EUR | 1.9M EUR | 1.21M EUR | 237K EUR | 386K EUR |
| Depreciation and amortization | 4.48M EUR | 2.72M EUR | 2.36M EUR | 1.93M EUR | 1.66M EUR |
| Operating income | −82.94M EUR | −58.81M EUR | −45.1M EUR | −32.5M EUR | −26.24M EUR |
| Net income | −90.09M EUR | −59.24M EUR | −43.21M EUR | −31.23M EUR | −27.62M EUR |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
